Literature DB >> 12045510

Effectiveness and cost-effectiveness analysis of neuroreflexotherapy for subacute and chronic low back pain in routine general practice: a cluster randomized, controlled trial.

Francisco M Kovacs1, Joan Llobera, Victor Abraira, Pablo Lázaro, Francisco Pozo, David Kleinbaum.   

Abstract

STUDY
DESIGN: A cluster randomized, controlled trial was performed.
OBJECTIVES: To assess the clinical effectiveness and cost-effectiveness of adding patients' referral to neuroreflexotherapy intervention to the usual management of subacute and chronic low back pain in routine general practice. SUMMARY OF BACKGROUND DATA: Neuroreflexotherapy consists of the temporary implantation of epidermal devices in trigger points in the back and referred tender points in the ear. The efficacy of this procedure for treating subacute and chronic low back pain has been demonstrated in previous randomized, double-blind, controlled clinical trials.
METHODS: Twenty-one primary care physicians working in seven primary care centers of the Spanish National Health Service in Palma de Mallorca, Spain, were randomly assigned to the intervention group (n = 11) or the control group (n = 10). The physicians recruited patients who had low back pain that had lasted for 14 or more days despite drug treatment and who did not meet criteria for surgery. The 45 patients recruited by physicians from the control group were treated according to the standard protocol, whereas the 59 patients recruited by physicians from the intervention group were, in addition, referred to neuroreflexotherapy intervention. The analysis of variables was performed taking into account that physicians, not patients, were randomly assigned.
RESULTS: Patients underwent clinical evaluations at baseline and 15, 60, and 365 days later. At baseline, median intensity of pain was higher in patients undergoing neuroreflexotherapy than in control patients (visual analogue scale, 6.07; range, 4.67-8.80 vs. 5.15, range 4.11-8.00) and median duration of pain was also higher (48.1, range 28.4-211.1 vs. 17.5, range 15.0-91.5 days). At the last follow-up visit, patients treated with neuroreflexotherapy showed greater improvement than did control patients in low back pain (visual analogue scale, 5.5; range, 3.7-8.8 vs. 1.9; range, -1.2-3.0; P < 0.001); referred pain (visual analogue scale, 3.6; range, 2.7-7.3 vs. 0.6; range, -1.5-2.0; P = 0.001); and disability (Roland-Morris scale, 8.7; range, 2.0-13.3 vs. 2.0; range, -1.5-6.7; P = 0.007). Moreover, neuroreflexotherapy intervention was associated with a significantly (P < 0.035) lower number of consultations to private or public specialists, fewer indications of radiographs by primary care physicians, lower cost of drug treatment, and less duration of sick leave throughout the follow-up period. There were also differences in favor of neuroreflexotherapy intervention in the cost-effectiveness ratio for pain, disability, and quality of life that persisted in the most optimistic, the most conservative, and the average (break-even case) assumptions.
CONCLUSIONS: Referral to neuroreflexotherapy intervention improves the effectiveness and cost-effectiveness of the management of nonspecific low back pain.

Entities:  

Mesh:

Year:  2002        PMID: 12045510     DOI: 10.1097/00007632-200206010-00004

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  16 in total

Review 1.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

2.  The social tariff of EQ-5D is not adequate to assess quality of life in patients with low back pain.

Authors:  Javier Zamora; Francisco Kovacs; Víctor Abraira; Carmen Fernández; Pablo Lázaro
Journal:  Qual Life Res       Date:  2006-11-17       Impact factor: 4.147

Review 3.  Value-based care in the management of spinal disorders: a systematic review of cost-utility analysis.

Authors:  Santoshi S Indrakanti; Michael H Weber; Steven K Takemoto; Serena S Hu; David Polly; Sigurd H Berven
Journal:  Clin Orthop Relat Res       Date:  2012-04       Impact factor: 4.176

4.  Pain regulation and health-related quality of life after thoracolumbar fractures of the spine.

Authors:  Daniel Briem; Aryan Behechtnejad; Alexander Ouchmaev; Matthias Morfeld; Karin Schermelleh-Engel; Michael Amling; Johannes M Rueger
Journal:  Eur Spine J       Date:  2007-05-23       Impact factor: 3.134

Review 5.  Content and outcome of usual primary care for back pain: a systematic review.

Authors:  Simon Somerville; Elaine Hay; Martyn Lewis; Julie Barber; Danielle van der Windt; Jonathan Hill; Gail Sowden
Journal:  Br J Gen Pract       Date:  2008-11       Impact factor: 5.386

Review 6.  Neuroreflexotherapy for non-specific low-back pain.

Authors:  G Urrútia; A K Burton; A Morral; X Bonfill; G Zanoli
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 7.  Cost-effectiveness of general practice care for low back pain: a systematic review.

Authors:  Chung-Wei Christine Lin; Marion Haas; Chris G Maher; Luciana A C Machado; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2011-01-04       Impact factor: 3.134

8.  Avoidable costs of physical treatments for chronic back, neck and shoulder pain within the Spanish National Health Service: a cross-sectional study.

Authors:  Pedro Serrano-Aguilar; Francisco M Kovacs; Jose M Cabrera-Hernández; Juan M Ramos-Goñi; Lidia García-Pérez
Journal:  BMC Musculoskelet Disord       Date:  2011-12-21       Impact factor: 2.362

9.  Are complementary therapies and integrative care cost-effective? A systematic review of economic evaluations.

Authors:  Patricia M Herman; Beth L Poindexter; Claudia M Witt; David M Eisenberg
Journal:  BMJ Open       Date:  2012-09-03       Impact factor: 2.692

10.  The use of risk sharing tools for post adoption surveillance of a non pharmacological technology in routine practice: results after one year.

Authors:  Carlos Campillo-Artero; Francisco M Kovacs
Journal:  BMC Health Serv Res       Date:  2013-05-20       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.